RG-6333

N/A

Report date: 2026/03/26 14:17:51

Base Information

Drug NameRG-6333

Drug Alias NameRO-7443904

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD19Anti-CD28

TargetsB-lymphocyte antigen CD19T-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItalyDenmark +[6]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A